title: The management of lomustine overdose in malignant glioma patients.
abstract: Lomustine is an oral alkylating drug commonly used for brain tumor patients. Recently, the lomustine-containing PCV polychemotherapy regime (procarbazine, CCNU/lomustine, and vincristine) in combination with radiotherapy has become the standard of care for anaplastic oligodendroglioma with 1p/19q codeletion and high-risk low-grade glioma. Here, we review the literature of all reported cases of lomustine overdose, highlight complications by exemplifying a case of inadvertent lomustine overdose, and outline the management of this potential complication of outpatient PCV therapy.
authors.affiliation: Department of Neurology, University Hospital Zurich, Zurich, Switzerland (H.-G.W., I.T., A.P., M.W., G.T.); Department of Medical Oncology , University Hospital Zurich , Zurich , Switzerland (C.R.); Neuroscience Center Zurich , University of Zurich and ETH Zurich , Zurich , Switzerland (H.-G.W., I.T., A.P., M.W., G.T.).
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Wirsching
authors.affiliation: Department of Neurology, University Hospital Zurich, Zurich, Switzerland (H.-G.W., I.T., A.P., M.W., G.T.); Department of Medical Oncology , University Hospital Zurich , Zurich , Switzerland (C.R.); Neuroscience Center Zurich , University of Zurich and ETH Zurich , Zurich , Switzerland (H.-G.W., I.T., A.P., M.W., G.T.).
authors.forename: Isabel
authors.initials: I
authors.lastname: Tritschler
authors.affiliation: Department of Neurology, University Hospital Zurich, Zurich, Switzerland (H.-G.W., I.T., A.P., M.W., G.T.); Department of Medical Oncology , University Hospital Zurich , Zurich , Switzerland (C.R.); Neuroscience Center Zurich , University of Zurich and ETH Zurich , Zurich , Switzerland (H.-G.W., I.T., A.P., M.W., G.T.).
authors.forename: Antonella
authors.initials: A
authors.lastname: Palla
authors.affiliation: Department of Neurology, University Hospital Zurich, Zurich, Switzerland (H.-G.W., I.T., A.P., M.W., G.T.); Department of Medical Oncology , University Hospital Zurich , Zurich , Switzerland (C.R.); Neuroscience Center Zurich , University of Zurich and ETH Zurich , Zurich , Switzerland (H.-G.W., I.T., A.P., M.W., G.T.).
authors.forename: Christoph
authors.initials: C
authors.lastname: Renner
authors.affiliation: Department of Neurology, University Hospital Zurich, Zurich, Switzerland (H.-G.W., I.T., A.P., M.W., G.T.); Department of Medical Oncology , University Hospital Zurich , Zurich , Switzerland (C.R.); Neuroscience Center Zurich , University of Zurich and ETH Zurich , Zurich , Switzerland (H.-G.W., I.T., A.P., M.W., G.T.).
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
authors.affiliation: Department of Neurology, University Hospital Zurich, Zurich, Switzerland (H.-G.W., I.T., A.P., M.W., G.T.); Department of Medical Oncology , University Hospital Zurich , Zurich , Switzerland (C.R.); Neuroscience Center Zurich , University of Zurich and ETH Zurich , Zurich , Switzerland (H.-G.W., I.T., A.P., M.W., G.T.).
authors.forename: Ghazaleh
authors.initials: G
authors.lastname: Tabatabai
keywords: CCNU; PCV; glioma; lomustine; myelosuppression; overdose